An observational study in PATIENTS WITH UNEXPLAINED BLEEDING DISORDERS, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Completed at 1 site in Italy. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational
Creation of an Italian network for unexplained bleeding disorders, using integrated multi-omics approaches to improve diagnosis, optimize patient management, and identify novel therapeutic targets.
Rare diseases affect millions of people across Europe. Many individuals with unexplained bleeding disorders live for years without a diagnosis, which can lead to serious health consequences. Although new laboratory and genetic tests have improved diagnosis, about one-third of patients still have no identified cause for their condition. This project aims to create a network of Italian centres working together to improve diagnosis through advanced biological and genetic analyses. By identifying the underlying causes of these disorders, we hope to provide better care, support the development of new treatments, and avoid unnecessary therapies that may have harmful side effects.
515 studies on the registry are indexed under Hemostatic Disorders; 72 are open to participants now.
This study's enrollment of 122 is above the median of 100 across 233 observational studies indexed under Hemostatic Disorders.
Browse Hemostatic Disorders studies →Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 232 studies on the registry; 83 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Homogenous population of probands with unexplained bleedings following a standardized and shared diagnostic algorithm (i.e., patients with an abnormal bleeding score and a normal state-of-the-art coagulation and platelet function test results).
The study will enrol both adult and pediatric patients recruited at the Haemostasis and Thrombosis Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and at participating centres (University Hospital Policlinico Giovanni XXIII, Bari), as well as their first- and second-degree relatives, regardless of whether they are affected by bleeding symptoms
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
cases with unexplained bleeding disorders
patients' relatives with bleeding history
patients' relatives with no bleeding history
Epigenetic analysis - methylation
Genome-wide methylation profile distinguishing patients with bleeding disorders from healthy individuals.
Time frame: within one year from the enrollment
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in May 2025, 23 months.
Of 103 non-industry observational studies under Hemostatic Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 62. This study's 23 months is below that.
Counting every sponsor, half of 122 studies reached it within 31 months; a quarter within 11 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico →